Through the inhibition of cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death 1 ligand-1 (PD-L1), ICIs bolster the host’s immune system to effectively recognize and target tumor cells [2]. Here, CTLA4 is linked to neoplasm.